Published in AIDS Weekly, February 11th, 2002
Following recent discussions with the U.S. Food and Drug Administration (FDA), Triangle now plans to submit a New Drug Application (NDA) in fall 2002 for Coviracil in the treatment of HIV. The company expects Coviracil to become its first product for which an NDA is submitted, marking a critical milestone in the company's history.
Triangle further intends to terminate development of Coactinon, another of its HIV compounds. The company recently completed a planned interim analysis of 24-week data from study...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.